The professor of neurology and founding chair of the John T. Macdonald Foundation Department of Human Genetics at the University of Miami spoke about how the risk of Alzheimer disease differs between ethnic groups, despite being associated with the same genetic marker.
The DCTclock demonstrated a 37% increase in discrimination over the traditional cognitive assessments.
uMETHOD Health has implemented a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease.
The AMBAR trial is based off of the hypothesis that amyloid-beta is bound to albumin and circulates in plasma; extracting this plasma may in turn flush amyloid from the brain.
The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health spoke about how telemedicine in senior living communities can effectively decrease ED use by individuals with dementia.
The concept of cognitive reserve refers to one’s capacity to be resilient to age-related brain degeneration and disease-related pathology.
People who did not use trazodone had up to a 2-fold faster decline in MMSE score than those who used the drug.
The International Congress on the Future of Neurology will take place this Fall in New York City, converging experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.
Findings suggest that a subgroup of patients categorized as amyloid beta-negative may continue to accumulate the destructive protein and experience cognitive changes.
The research fellow at the University of Exeter spoke about the findings from her observational study which showed that living a favorable lifestyle could offset the risk for dementia, even if that risk is genetically linked. 


While single modality therapy is safe, feasible, and effective, researchers demonstrated that a combined modality shows greater domain-specific cognitive enhancements with higher transferability and sustainability.
Participants with high CSF Aβ1-42/tau and lower NPTX2 levels experienced greater decline throughout the 36 months than all other subgroups on memory acquisition, delayed recall, and CDR-sb.
The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.
While the clinical benefit of the therapy in Alzheimer is still unclear, the dihydropyridine calcium channel blocker increased blood flow by 20% compared to placebo in the brain’s memory and learning center, indicative of preserved cerebral autoregulation.
Two medical students who are conservatory-trained musicians describe a memorable performance at a center for older adults with dementia.
The systematic review and meta-analysis identified cNfL usefulness as a biomarker, with the potential to help differentiate between frontotemporal dementia and Alzheimer disease, as well as Parkinson disease from atypical parkinsonian syndromes.
Alzheimer and circulating cholesterol linked, obesity has a big impact on MS, mild traumatic brain injury difficulties persist, and other recent findings are summarized here.
Neurology News Network for the week ending June 8, 2019.
The findings from an analysis of more than 2000 plasma samples suggest that levels of low-density lipoprotein cholesterol, independent of APOE, are associated with early-onset Alzheimer disease—and that the APOB gene may play a role.
Results of the large, long-term, population-based study suggest that statin therapy in older adults who experience a concussion may help reduce the deleterious effects of brain injury.
The WHO guidelines specifically promote a healthy lifestyle, including regular exercise, not smoking, avoiding the harmful use of alcohol, maintaining a healthy weight and diet, and keeping healthy levels of blood pressure, cholesterol, and blood sugar.
How are you counseling patients and families about the risks and benefits of playing sports with repetitive head blows and the risk of CTE?
Suvorexant improved the mean total sleep time by 28.2 minutes for the patients receiving the treatment versus placebo, equating to a mean increase of 73.4 minutes with the orexin receptor antagonist.
